Natco Pharma AGM 2026: Rights Issue, Funding Plan, Agenda

What Natco Pharma disclosed to exchanges

Natco Pharma Limited has filed its annual report for the financial year 2025-26 with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The filing was accompanied by the notice for the company’s 43rd Annual General Meeting (AGM). The company’s disclosure letter was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, and dated September 4, 2026.

The disclosures matter because the AGM agenda combines routine statutory business with shareholder actions that link to the company’s capital plans. Separately, the company has also communicated board-level steps around a rights issue and fundraising.

43rd AGM date, time, and mode

Natco Pharma scheduled its 43rd AGM for Wednesday, September 30, 2026, at 11:00 am (IST). The meeting is set to be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company referenced compliance with Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The annual report and the AGM notice are accessible on the company’s investor relations website, as per the disclosure. For shareholders, the VC or OAVM format means participation is remote, and voting processes typically rely on electronic mechanisms.

AGM agenda: ordinary and special business

The AGM is planned to transact ordinary and special business. Items highlighted in the exchange-linked summary include adoption of the audited financial statements for FY2025-26. The notice also refers to confirmation of interim dividends.

The company indicated agenda items that include re-appointment of Director P.S.R.K. Prasad and ratification of cost auditor remuneration. In addition, the AGM includes a proposal to approve raising up to ₹2,000 crores through various securities issuances. The disclosure also notes that shareholders must vote remotely on key governance and capital-raising decisions.

Rights issue: board decision and key terms communicated

Natco Pharma informed the exchange that its Board of Directors, at a meeting held on September 25, 2026, decided to issue equity shares on a rights basis. The rights entitlement ratio stated was 2:21, meaning two equity shares for every 21 equity shares held.

The issue price communicated was ₹750 per share, including a premium of ₹748 per rights equity share. These details establish the basic economics of the rights issue for existing shareholders, subject to the process and timelines communicated through further announcements and record-date related disclosures.

Board meetings around fundraising and the rights issue process

Natco Pharma also disclosed that a board meeting was scheduled on September 25, 2026 to consider and approve matters connected to the rights issue. The company described the scope as including the specific terms of the rights issue, such as determination of the rights issue price and related payment mechanism, the rights entitlement ratio, the record date, and the timing of the rights issue.

Separately, Natco Pharma announced a board meeting on September 9, 2026 to consider raising capital through equity or other securities, subject to regulatory approvals, to support strategic growth initiatives. In another update, the company’s board approved a ₹1,300 crore rights issue of equity shares to existing shareholders on September 9, 2026.

These disclosures show multiple decision points: one around evaluating broader fundraising options and another around progressing a rights issue with defined terms.

Key dates and disclosed figures at a glance

Stock market snapshot mentioned in the update

A market snapshot line in the provided information references September 30, 2026 with two price points: 838.05 and 818.65. The disclosure extract does not specify what these two values represent (for example, open and close, or high and low). As presented, it indicates that the stock had traded around the ₹800-plus level around the AGM date reference.

What shareholders should track ahead of the AGM

For investors, the immediate checklist is procedural and document-driven. First is the FY26 annual report filing, which is the base document for the AGM’s financial statement adoption. Second is the AGM notice, which outlines the resolutions, including governance items and the proposed fundraising authorisation.

Third is the rights issue structure already communicated: ratio and price. Shareholders may also watch for any follow-up disclosures on the record date and timing, since those determine eligibility and key deadlines. The company has explicitly referred to remote voting for decisions that include capital raising and dividend-related items.

Why the combination of AGM and capital actions matters

An AGM typically covers standard statutory business, but in Natco Pharma’s case the notice and related disclosures place capital actions in the foreground. The rights issue and the broader authorisation to raise funds through various securities can affect the company’s capital structure and shareholder participation rights.

The disclosed rights issue terms provide a concrete basis for shareholders to evaluate the proposed fundraising route. At the same time, the separate reference to approval to raise up to ₹2,000 crores suggests that the company is also keeping multiple financing options open, subject to shareholder approval and regulatory processes.

Conclusion

Natco Pharma has filed its FY26 annual report and called its 43rd AGM for September 30, 2026 at 11:00 am via VC or OAVM, with resolutions spanning audited accounts, dividends, board matters, and capital raising. Alongside the AGM notice, the company has also disclosed steps toward a rights issue, including a 2:21 entitlement ratio and an issue price of ₹750 per share. The next set of updates to watch are any further disclosures on the rights issue record date, timing, and the outcome of shareholder voting on the fundraising authorisations.